Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 14.09.2026 | Accepted 16.09.2026 | Online 20.09.2026

NANOPARTICLE-BASED DRUG DELIVERY SYSTEMS FOR TARGETED CANCER THERAPY: CURRENT ADVANCES AND CHALLENGES

Dr. Camille Laurent

Department of Pharmaceutical Nanotechnology,

European Institute of Biomedical Sciences, Paris, France
E-mail: camille.laurent@example.com

Abstract.

Nanoparticle-based drug delivery has become a central strategy for improving the therapeutic index of anticancer agents by modifying pharmacokinetics, protecting unstable payloads, enabling combination treatment, and creating opportunities for tumor-selective delivery. This structured narrative review evaluates current advances in lipid, polymeric, protein, inorganic, and biomimetic nanoparticles for targeted cancer therapy, with particular attention to passive accumulation, ligand-mediated active targeting, stimuli-responsive release, tumor penetration, clinical translation, and manufacturing constraints. The evidence indicates that nanocarriers can substantially alter drug exposure and reduce selected formulation-related toxicities, but tumor accumulation remains heterogeneous and frequently inefficient. The classical enhanced permeability and retention (EPR) model is therefore increasingly supplemented by mechanistic concepts involving active endothelial transport, stromal interactions, immune clearance, and patient-specific tumor biology. Active targeting improves receptor-mediated binding and internalization when particles have already reached tumor tissue, but it does not automatically solve the systemic delivery problem. Stimuli-responsive and multifunctional systems are promising for spatially and temporally controlled release, although their added complexity can complicate characterization, scale-up, and regulatory assessment. The most clinically mature platforms remain liposomes, lipid nanoparticles, albumin-based systems, and selected polymeric formulations. Future progress will depend on rational nanoparticle engineering, biomarker-guided patient selection, quantitative imaging of delivery, reproducible manufacturing, and early integration of translational and regulatory requirements.

Keywords: nanoparticles; targeted drug delivery; cancer nanomedicine; liposomes; active targeting; EPR effect; tumor microenvironment; stimuli-responsive systems; clinical translation.

1. INTRODUCTION

Cancer therapy has increasingly shifted from nonspecific cytotoxic treatment toward strategies that seek to control where, when, and how therapeutic agents are exposed to malignant tissue. Conventional small-molecule chemotherapy remains indispensable, but its clinical usefulness may be limited by poor aqueous solubility, short circulation time, dose-limiting systemic toxicity, multidrug resistance, and insufficient concentrations at the tumor site. Nanoparticle-based drug delivery systems were developed to address several of

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 14.09.2026 Accepted 16.09.2026 Online 20.09.2026

these limitations by encapsulating or conjugating drugs within carriers whose physicochemical properties can be engineered independently of the active pharmaceutical ingredient (1,3,5).

Cancer nanomedicine includes lipid vesicles, lipid nanoparticles, polymeric nanoparticles and micelles, protein-based carriers, dendritic systems, inorganic particles, hybrid materials, and biomimetic formulations. These platforms can alter biodistribution, protect nucleic acids and labile molecules, co-deliver multiple agents, and create mechanisms for triggered or receptor-mediated uptake. The field has produced clinically established products and a large preclinical pipeline, but the gap between laboratory success and consistent patient benefit remains substantial (1,6,7).

Historically, passive tumor targeting has been explained by the enhanced permeability and retention (EPR) effect: structurally abnormal tumor vasculature can permit extravasation of macromolecules and nanoparticles, while impaired lymphatic drainage may prolong local retention. However, EPR intensity varies substantially among tumor types, lesions, patients, and treatment stages. A meta-analysis of preclinical studies reported that a small median fraction of an injected nanoparticle dose reaches solid tumors, emphasizing that accumulation is a major bottleneck rather than an automatic consequence of nanoscale formulation (2). More recent work has further challenged a purely gap-based model and highlighted transendothelial and active transport pathways in nanoparticle entry and retention (9).

Active targeting adds ligands such as antibodies, peptides, aptamers, carbohydrates, or small molecules to the nanoparticle surface. These ligands may enhance binding to receptors overexpressed on tumor cells or tumor-associated endothelium and can increase cellular internalization. Nevertheless, targeted nanoparticles must still survive circulation, avoid rapid mononuclear phagocyte system clearance, reach the tumor, penetrate the extracellular matrix, and maintain ligand accessibility in the presence of a protein corona. Thus, active targeting is best viewed as one step within a multistage delivery process rather than a substitute for adequate tumor exposure (4,8).

Recent generations of nanocarriers attempt to respond to pathophysiological cues such as acidic pH, redox gradients, enzymes, hypoxia, or externally applied heat, ultrasound, magnetic fields, or light. These systems aim to reduce premature release in blood and increase drug release within the tumor microenvironment or intracellular compartments. In parallel, precision nanomedicine seeks to match nanocarrier design to measurable patient and tumor characteristics instead of relying on a universal formulation (3,12).

The objective of this article is to synthesize current evidence on nanoparticle platforms used for targeted cancer therapy, compare passive, active, and stimuli-responsive delivery strategies, examine representative clinically established nanoformulations, and critically analyze the biological, technological, manufacturing, and regulatory barriers that continue to limit translation. The article is organized according to the IMRAD framework and is intended to support scientific discussion of contemporary cancer drug-delivery research.

2. MATERIALS AND METHODS

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 14.09.2026 Accepted 16.09.2026 Online 20.09.2026

This work was designed as a structured narrative review with an IMRAD presentation. Peer-reviewed literature was identified through PubMed-indexed sources, major publisher databases, and reference tracing. Priority was given to high-impact reviews, translational analyses, mechanistic studies, and recent publications from 2015 to 2026, while selected older landmark literature was considered when necessary to explain fundamental concepts. Search concepts included combinations of "cancer nanomedicine," "nanoparticle drug delivery," "liposome cancer," "active targeting," "EPR effect," "tumor penetration," "stimuli-responsive nanoparticle," "clinical translation," and "nanoparticle manufacturing."

Articles were included when they addressed at least one of the following domains: (i) nanoparticle platform design and payload delivery; (ii) biological mechanisms governing tumor accumulation and intratumoral transport; (iii) active ligand-mediated targeting; (iv) stimuli-responsive delivery; (v) clinically established or clinically investigated anticancer nanomedicines; or (vi) translational barriers including safety, scale-up, quality control, patient heterogeneity, and regulatory evaluation. Publications limited to non-oncologic applications without transferable drug-delivery principles were excluded from the core synthesis.

The evidence was synthesized qualitatively into four analytic dimensions: platform properties, targeting mechanism, therapeutic functionality, and translational readiness. Because the included literature is heterogeneous in tumor model, nanoparticle composition, dose, and outcome definitions, pooled effect-size calculation was not performed. The ordinal platform scores presented in Figure 2 are conceptual synthesis tools derived from comparative characteristics in the reviewed literature; they are not experimental measurements or meta-analytic estimates.




Figure 1. Multistage pathway for nanoparticle-mediated targeted cancer drug delivery.

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 14.09.2026 Accepted 16.09.2026 Online 20.09.2026

3. RESULTS

3.1. Major nanoparticle platforms for anticancer delivery

The literature consistently shows that no single nanocarrier platform is optimal for all payloads and cancer settings. Liposomes and lipid nanoparticles combine strong biocompatibility with the ability to carry hydrophilic, hydrophobic, and nucleic-acid payloads. Their surface can be PEGylated or decorated with targeting ligands, and their manufacturing history provides a comparatively mature translational foundation. Recent reviews emphasize continued expansion of lipid systems toward tumor vaccination, RNA delivery, combination therapy, and stimuli-responsive release (14,15).

Polymeric nanoparticles based on materials such as PLGA, PEG-containing copolymers, polycaprolactone, and biodegradable block copolymers offer flexible control of degradation, drug release, size, and surface functionality. Polymeric micelles are especially suitable for hydrophobic compounds, whereas solid polymer matrices can provide sustained release. Their main challenges include polymer heterogeneity, residual solvents, batch-to-batch variability, sterilization constraints, and the need to correlate in vitro release behavior with in vivo performance (3,5).

Protein-based nanoparticles, including albumin-based carriers, use endogenous or biomimetic materials to improve solubility and transport of poorly soluble drugs. Their advantages include biodegradability and established clinical precedent, but protein structure, aggregation, source variability, and complex interactions with receptors and the immune system require careful control. Inorganic nanoparticles—including gold, iron oxide, silica, and other nanostructures—provide unique optical, magnetic, or thermal properties that are valuable for imaging, photothermal therapy, radiosensitization, and theranostics. Their long-term persistence, biodegradation, and organ accumulation remain important safety considerations (1,6).

Biomimetic systems, including cell-membrane-coated nanoparticles and vesicle-inspired carriers, attempt to reproduce natural recognition or immune-evasion properties. These approaches are highly attractive for precision delivery but are generally less mature with respect to scalable manufacturing, compositional definition, and regulatory standardization. The practical design choice therefore reflects a trade-off between functionality and translational simplicity.

Table 1. Comparative characteristics of major nanoparticle platforms in cancer therapy.

Platform	Typical material	Payloads	Principal strengths	Key limitations
Liposomes / LNPs	Lipids, cholesterol, ionizable lipids	Small molecules, proteins, RNA	High biocompatibility; versatile loading; strong clinical precedent	Leakage, oxidation, stability, complex CMC for advanced targeting

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 14.09.2026 Accepted 16.09.2026 Online 20.09.2026

Platform	Typical material	Payloads	Principal strengths	Key limitations
Polymeric nanoparticles	PLGA, PEG copolymers, polyesters	Hydrophobic drugs, combinations, biologics	Tunable degradation and sustained release	Polymer heterogeneity, solvent removal, scale-up reproducibility
Polymeric micelles	Amphiphilic block copolymers	Poorly soluble small molecules	High solubilization; small size	Dilution-induced instability; limited loading for some drugs
Protein / albumin carriers	Albumin or other proteins	Hydrophobic drugs, conjugates	Biodegradable; clinically familiar materials	Protein aggregation; source and structure control
Inorganic nanoparticles	Gold, silica, iron oxide, others	Drugs, imaging agents, energy-responsive systems	Theranostics; optical/magnetic functions	Long-term fate, biodegradation and accumulation concerns
Biomimetic nanoparticles	Cell membranes, vesicle-inspired surfaces	Drugs, proteins, nucleic acids	Immune camouflage; complex biological recognition	Manufacturing complexity; variable composition

3.2. Passive accumulation, active targeting, and tumor penetration

Passive targeting remains foundational because intravenously administered nanoparticles must first reach tumor-associated vasculature before any ligand can engage a cellular receptor. EPR-related accumulation can occur in many experimental tumors, but the magnitude and spatial distribution are highly heterogeneous. Vascular perfusion, fenestration pattern, stromal density, extracellular matrix composition, tumor-associated macrophages, interstitial pressure, and lymphatic function all influence delivery. The widely cited analysis by Wilhelm et al. found a median tumor delivery of approximately 0.7% of the injected nanoparticle dose across compiled preclinical studies, illustrating the scale of the systemic delivery problem (2).

Recent mechanistic analyses indicate that nanoparticle transport across tumor endothelium cannot be explained solely by static interendothelial gaps. Evidence for transcellular transport and active endothelial processes has contributed to a broader “active transport and retention” perspective. This does not eliminate the relevance of vascular

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 14.09.2026 Accepted 16.09.2026 Online 20.09.2026

leakiness, but it highlights the need to characterize the specific transport biology of individual tumors and nanoparticle types (9).

Active targeting may increase local cell binding, receptor-mediated endocytosis, and intracellular drug delivery. Common targets include HER2, EGFR, folate receptor, transferrin receptor, integrins, CD44, and tumor-associated vascular markers. Antibodies provide high affinity and specificity but increase size and manufacturing complexity; peptides are smaller and may penetrate more effectively; aptamers offer programmable recognition; and folate or carbohydrate ligands can provide relatively simple conjugation strategies. Ligand density must be optimized because very high surface coverage can increase opsonization, alter pharmacokinetics, or promote binding-site barriers near blood vessels (4,8).

Tumor penetration is a separate problem from tumor accumulation. Larger nanoparticles may remain near vessels, whereas smaller systems may diffuse more deeply but can be cleared more rapidly or carry less drug. Dense collagen, hyaluronan-rich matrices, cancer-associated fibroblasts, high interstitial pressure, and heterogeneous perfusion can prevent uniform exposure. Strategies under investigation include size-switchable systems, matrix-degrading or remodeling approaches, tumor-penetrating peptides, vascular normalization, and local or regional administration. Rational design therefore requires optimization across circulation, extravasation, penetration, cellular uptake, and intracellular release rather than maximizing a single parameter (5,9,13).

Table 2. Targeting strategies for nanoparticle-based cancer therapy.

Strategy	Mechanism	Advantages	Main limitations
Passive tumor accumulation	Tumor vascular abnormalities and retention mechanisms	No targeting ligand required; simpler formulation	Strong patient- and lesion-level heterogeneity
Antibody / fragment targeting	Binding to tumor-associated surface antigen	High affinity and molecular specificity	Cost, immunogenicity, size, conjugation complexity
Peptide targeting	Receptor binding or tumor-penetrating motifs	Small size; flexible chemistry	Proteolysis and affinity limitations
Aptamer targeting	Nucleic-acid recognition of cell-surface targets	Programmable and chemically modifiable	Nuclease stability and manufacturing controls
Small-molecule targeting	Folate and other receptor-binding moieties	Simple chemistry and low molecular weight	Target expression can be heterogeneous
Stimuli-responsive targeting	pH, redox, enzymes, heat, light, ultrasound,	Conditional release; improved spatial	Added formulation and validation complexity

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 14.09.2026 Accepted 16.09.2026 Online 20.09.2026

Strategy	Mechanism	Advantages	Main limitations
	magnetic field	control	




Figure 2. Conceptual literature-based comparison of nanoparticle platforms. Scores are qualitative ordinal synthesis (1 = relatively low, 5 = relatively high), not experimental measurements.

3.3. Stimuli-responsive, combination, and multifunctional nanomedicine

The tumor microenvironment provides endogenous triggers that can be exploited for conditional drug release. Acid-sensitive linkers or ionizable materials can respond to extracellular tumor acidity or endosomal acidification. Redox-responsive formulations exploit differences in glutathione or reactive oxygen species, while enzyme-sensitive materials respond to proteases or other tumor-associated enzymes. Exogenous triggers—including heat, light, ultrasound, and magnetic fields—allow additional temporal control when energy can be delivered safely to the tumor region. These approaches are attractive because they separate systemic transport from local drug activation, but the trigger must be sufficiently different between tumor and normal tissue to create a meaningful therapeutic window.

Nanoparticles are also well suited for combination therapy. Co-encapsulation can synchronize the pharmacokinetics of two drugs, combine chemotherapy with nucleic acids, or integrate immunotherapy with cytotoxic treatment. Theranostic systems couple treatment with imaging so that delivery can be visualized or quantified. Such multifunctionality is scientifically appealing, but every added component increases the number of critical quality attributes that must be controlled. Complex formulations may

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 14.09.2026 Accepted 16.09.2026 Online 20.09.2026

therefore achieve excellent preclinical performance while becoming difficult to manufacture reproducibly or evaluate mechanistically in clinical trials (6,11).

An important emerging principle is that functionality should be added only when it addresses a clearly defined biological barrier. Precision nanoparticle design prioritizes the "right" carrier for a measurable delivery problem rather than maximizing complexity. This approach aligns with translational analyses that recommend early attention to disease biology, target tissue exposure, safety, patient selection, and manufacturability (3,6).

3.4. Clinical progress and translational evidence

Clinical experience demonstrates that nanomedicine can improve cancer therapy, but benefits are often formulation-specific rather than universal. Liposomal doxorubicin modifies doxorubicin pharmacokinetics and reduces selected toxicities; albumin-bound paclitaxel avoids the need for Cremophor EL; liposomal irinotecan changes irinotecan exposure; and fixed-ratio liposomal combinations demonstrate how nanoparticles can coordinate multidrug delivery. These examples validate the pharmaceutical value of nanocarriers even when they do not provide highly selective tumor-cell targeting.

Translational surveys show that the number of preclinical nanoparticle concepts greatly exceeds the number of clinically established products. Common reasons include inadequate demonstration of superiority over standard therapy, poor reproducibility between animal models and human tumors, unexpected biodistribution, immune reactions, difficulty defining dose based on both carrier and payload, and manufacturing challenges. Clinical success therefore requires a clear product advantage that is large enough to justify added formulation complexity (6,7,10).

Recent reviews from 2025–2026 continue to identify lipid-based nanocarriers as among the most clinically mature platforms while emphasizing persistent barriers to active targeting, reproducible tumor accumulation, and large-scale manufacturing. Current development is increasingly focused on patient stratification, imaging-supported delivery assessment, tumor microenvironment modulation, and integration of nucleic-acid or immune-modulating payloads (14,15).

Table 3. Representative clinically established nanoparticle-enabled anticancer formulations and translational lessons.

Example	Platform	Primary formulation advantage	Translational lesson
Pegylated liposomal doxorubicin	Liposomal anthracycline	Altered distribution and reduced peak free-drug exposure	Nanocarriers can improve therapeutic index without requiring receptor targeting
Albumin-bound paclitaxel	Protein nanoparticle	Solubilization without Cremophor EL; modified disposition	Carrier material can solve formulation and tolerability problems
Liposomal irinotecan	Liposomal	Prolonged	Pharmacokinetic

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 14.09.2026 Accepted 16.09.2026 Online 20.09.2026

Example	Platform	Primary formulation advantage	Translational lesson
	topoisomerase inhibitor	encapsulated-drug exposure	redesign can be clinically useful
Liposomal daunorubicin/cytarabine	Dual-drug liposome	Maintains coordinated drug ratio	Nanocarriers can control combination-drug exposure

3.5. Safety, manufacturing, and regulatory challenges

Nanoparticle safety depends on both the payload and the carrier. Particle size, charge, shape, surface chemistry, degradation products, complement activation, protein corona formation, and accumulation in liver or spleen can influence tolerability. Long-circulating systems may reduce exposure in some normal tissues but prolong exposure in others. Repeated administration can also change pharmacokinetics through immune recognition. Safety evaluation must therefore characterize the complete formulation rather than assume that an approved drug retains the same behavior after nanoencapsulation.

Manufacturing is a major translational bottleneck. Critical quality attributes include particle-size distribution, morphology, surface charge, drug loading, encapsulation efficiency, free-drug fraction, ligand density, lipid or polymer composition, impurity profile, sterility, stability, release kinetics, and—where relevant—nucleic-acid integrity. Scale-up can alter mixing, solvent exchange, shear forces, and self-assembly, producing nanoparticles that are nominally similar but biologically different. Regulatory guidance for liposomal and nanomaterial-containing drug products therefore emphasizes detailed chemistry, manufacturing, controls, pharmacokinetics, and product characterization.

Complex active-targeted or stimuli-responsive nanoparticles face an additional challenge: demonstrating which component produces clinical benefit. If a formulation contains a core carrier, PEG coating, targeting ligand, imaging label, and trigger-responsive linker, failures may be difficult to diagnose and lot release testing becomes more demanding. Translationally successful platforms are likely to balance biological sophistication with analytical tractability and manufacturability.

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 14.09.2026 Accepted 16.09.2026 Online 20.09.2026




Figure 3. Conceptual translational funnel for nanoparticle-based cancer therapeutics.

4. DISCUSSION

The central finding of this review is that nanoparticle-based drug delivery is best understood as a systems-engineering problem rather than a single targeting technology. A nanocarrier must maintain stability in formulation, survive dilution in blood, interact favorably with plasma proteins, avoid rapid clearance, traverse or interact with tumor vasculature, penetrate heterogeneous tissue, enter the intended cell population, release the payload at the correct rate, and ultimately produce a clinically meaningful advantage over existing therapy. Failure at any stage can erase benefits achieved at earlier stages.

The classical distinction between passive and active targeting can oversimplify this process. Passive delivery does not imply an absence of biology: vascular transport, endothelial trafficking, macrophage interactions, stromal retention, and lymphatic pathways are active determinants of nanoparticle disposition. Similarly, active targeting does not necessarily increase the total amount of nanoparticle reaching a tumor; it may primarily increase cellular binding and internalization among particles that have already accumulated locally. This explains why excellent in vitro receptor targeting frequently fails to translate into dramatic in vivo tumor selectivity (2,4,9).

A second major issue is heterogeneity. Tumors of the same histologic type can differ in perfusion, vascular permeability, extracellular matrix, immune-cell composition, receptor expression, necrosis, and prior-treatment effects. A fixed nanoparticle design is therefore unlikely to perform uniformly across all patients. Precision nanomedicine proposes the use of biomarkers and imaging to identify patients whose tumors exhibit the relevant delivery phenotype. For example, a targeted formulation may be most useful when both nanoparticle access and receptor expression are demonstrated rather than inferred from diagnosis alone (3).

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 04 Received 14.09.2026 Accepted 16.09.2026 Online 20.09.2026

Third, nanomedicine development should distinguish formulation success from tumor-targeting success. Clinically established formulations often provide value by solving solubility, pharmacokinetic, or toxicity problems rather than achieving dramatic tumor-specific accumulation. This is not a limitation of the field; it is evidence that clinically relevant nanoparticle design should begin with a defined therapeutic problem. If a drug fails because of insolubility, a simple carrier may be sufficient. If it fails because of off-target systemic toxicity, long-circulating or locally activated formulations may help. If it fails because of intracellular target access, receptor-mediated uptake or endosomal escape may become the key design objective.

Stimuli-responsive systems can improve temporal and spatial control, but response thresholds must be clinically realistic. Tumor pH, enzyme activity, redox state, and oxygenation are variable and often overlap with normal pathological tissues. Systems that respond strongly in simplified cell culture may exhibit weaker selectivity in vivo. Externally triggered systems offer greater operator control but require appropriate energy penetration and clinically compatible devices. Each added feature should therefore be connected to a measurable biological parameter and accompanied by robust analytical methods.

The next generation of targeted cancer nanomedicine is likely to integrate quantitative imaging, patient-derived models, pharmacokinetic modeling, artificial intelligence, and adaptive formulation design. Imaging may help quantify carrier accumulation before exposing a patient to a therapeutic dose. Organoids and microphysiological systems can test interactions with human tumor and stromal compartments. Physiologically based pharmacokinetic models can connect nanoparticle properties with organ distribution. Machine learning may support formulation optimization, but high-quality standardized datasets will be essential.

Clinical translation also requires earlier attention to manufacturability. A formulation that depends on narrow size windows, complex ligand orientation, multi-step conjugation, or unstable materials may be difficult to reproduce at commercial scale. Quality-by-design principles should identify critical material attributes and process parameters during preclinical development rather than after efficacy has already been demonstrated. This is particularly important for combination nanomedicines and personalized products, where release testing and shelf-life can become major practical constraints.

Finally, regulatory science must evolve alongside platform complexity. Nanoparticle drug products cannot always be characterized by the same parameters used for conventional small molecules because carrier structure can determine pharmacokinetics and biological performance. Regulators therefore require detailed physicochemical characterization, stability data, manufacturing controls, and clinically relevant pharmacokinetic assessment. Development programs that treat the nanocarrier as an integral component of the drug product are more likely to generate interpretable evidence and reproducible quality.

5. CONCLUSION

Nanoparticle-based drug delivery has established an important role in cancer therapeutics by improving drug solubility, reshaping pharmacokinetics, protecting labile

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 14.09.2026 | Accepted 16.09.2026 | Online 20.09.2026

payloads, enabling combination therapy, and supporting targeted or triggered delivery. Lipid, polymeric, protein, inorganic, and biomimetic platforms each offer distinct strengths, but no platform is universally optimal.

The major scientific challenge is not simply creating nanoparticles that bind cancer cells; it is achieving sufficient, reproducible delivery through the entire sequence of systemic and intratumoral barriers. EPR-based accumulation is heterogeneous, active targeting depends on prior tumor access, and multifunctional systems introduce analytical and manufacturing complexity. The most promising development strategy is therefore mechanism-based and patient-aware: define the delivery barrier, select the simplest carrier that can overcome it, verify delivery quantitatively, and integrate manufacturing and regulatory requirements from the beginning.

Future clinical progress will depend on biomarker-guided patient selection, quantitative imaging of nanoparticle distribution, improved human-relevant models, scalable manufacturing, robust quality control, and a clearer connection between nanocarrier design and measurable clinical benefit. Under these conditions, targeted nanomedicine can continue to evolve from a broad technological concept into a more predictable component of precision oncology.

REFERENCES

1. Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: Progress, challenges and opportunities. Nature Reviews Cancer, 17(1), 20–37. https://doi.org/10.1038/nrc.2016.108
2. Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016). Analysis of nanoparticle delivery to tumours. Nature Reviews Materials, 1, 16014. https://doi.org/10.1038/natrevmats.2016.14
3. Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021). Engineering precision nanoparticles for drug delivery. Nature Reviews Drug Discovery, 20(2), 101–124. https://doi.org/10.1038/s41573-020-0090-8
4. Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018). Progress and challenges towards targeted delivery of cancer therapeutics. Nature Communications, 9, 1410. https://doi.org/10.1038/s41467-018-03705-y
5. Blanco, E., Shen, H., & Ferrari, M. (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnology, 33(9), 941–951. https://doi.org/10.1038/nbt.3330
6. Zhang, P., Xiao, Y., Sun, X., Lin, X., Koo, S., Yaremenko, A. V., Qin, D., Kong, N., Farokhzad, O. C., & Tao, W. (2023). Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects. Med, 4(3), 147–167. https://doi.org/10.1016/j.medj.2022.12.001
7. Anselmo, A. C., & Mitragotri, S. (2019). Nanoparticles in the clinic: An update. Bioengineering & Translational Medicine, 4(3), e10143. https://doi.org/10.1002/btm2.10143

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 04 | Received 14.09.2026 | Accepted 16.09.2026 | Online 20.09.2026

8. Dutta, B., Barick, K. C., & Hassan, P. A. (2021). Recent advances in active targeting of nanomaterials for anticancer drug delivery. Advances in Colloid and Interface Science, 296, 102509. https://doi.org/10.1016/j.cis.2021.102509
9. Nguyen, L. N. M., Ngo, W., Lin, Z. P., Sindhwani, S., MacMillan, P., Mladjenovic, S. M., & Chan, W. C. W. (2024). The mechanisms of nanoparticle delivery to solid tumours. Nature Reviews Bioengineering, 2, 201–213. https://doi.org/10.1038/s44222-024-00154-9
10. He, H., Liu, L., Morin, E. E., Liu, M., & Schwendeman, A. (2019). Survey of clinical translation of cancer nanomedicines—Lessons learned from successes and failures. Accounts of Chemical Research, 52(9), 2445–2461.
11. Sun, D., Zhou, S., & Gao, W. (2020). What went wrong with anticancer nanomedicine design and how to make it right. ACS Nano, 14(10), 12281–12290.
12. van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F., Mulder, W. J. M., & Lammers, T. (2019). Smart cancer nanomedicine. Nature Nanotechnology, 14, 1007–1017.
13. Golombek, S. K., May, J. N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018). Tumor targeting via EPR: Strategies to enhance patient responses. Advanced Drug Delivery Reviews, 130, 17–38.
14. Liu, Y., Zhang, Y., Li, H., & Hu, T. Y. (2025). Recent advances in the bench-to-bedside translation of cancer nanomedicines. Acta Pharmaceutica Sinica B, 15(1), 97–122. https://doi.org/10.1016/j.apsb.2024.12.007
15. Cheng, Z., Huang, H., Yin, M., & Liu, H. (2025). Applications of liposomes and lipid nanoparticles in cancer therapy: Current advances and prospects. Experimental Hematology & Oncology, 14, 11. https://doi.org/10.1186/s40164-025-00602-1